Natco Pharma Launches Affordable Semaglutide Generic Injection in India
Hyderabad, India, March 20, 2026 – Natco Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) announced the launch of Semaglutide Injection (multi dose vials) in the Indian market, coinciding with the patent expiry.The company received approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 to manufacture and market generic Semaglutide in India. Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
Natco Pharma plans to launch Semaglutide injection in multi dose vials of strengths 2mg/1.5ml, 4mg/3ml, and 8mg/3ml under the brand names SEMANAT™ and SEMAFULL™. The Multi dose vials will be priced at a maximum retail price (MRP) of INR 1,290 per month for the 2 mg/1.5ml & 4mg/3ml strengths, and INR 1,750 for the 8mg/3ml strength. A pen device is expected to launch in April 2026, priced at an MRP of INR 4,000, INR 4,200, and INR 4,500 per month for the 2mg/1.5ml, 4mg/3ml and 8mg/3ml strengths respectively.
Natco Pharma is the first company to offer generic Semaglutide in multi dose vials with customized syringes, and is also offering the product to third parties for co-marketing. The company states that this offering represents approximately 70% cost savings compared to the pen device and 90% cheaper than the innovator's brand, enhancing patient accessibility to GLP-1 therapy.
About Natco Pharma Limited
Natco Pharma Limited (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) develops, manufactures, and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The company operates 9 manufacturing sites and 2 R&D facilities in India, with facilities approved by regulatory authorities including the U.S. FDA, Brazil ANVISA, and Health Canada.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.